



**To:** Carter BloodCare Customers  
**From:** Hospital Relations  
**Date:** August 17, 2021  
**Re:** UPDATE\_COVID-19 Convalescent Plasma (CCP) Collection and Usage

## Background

Due to the increased demand for COVID-19 convalescent plasma (CCP), Carter BloodCare intends to resume collection of CCP on August 19, 2021. Based on recent average usage and with limited import opportunities, Carter BloodCare expects demand to outpace availability in the near future.

## Client Action

- Back orders should be expected.
- Orders will be primarily filled for transfusion.
- Stock orders for CCP will be determined on a case-by-case basis.
- Notify stakeholders of the fee increase for CCP. CCP will carry a **\$797.50 fee** at the Cost Recovery Rate for CCP Collection provided by the Biomedical Advanced Research and Development Authority (BARDA.) Carter BloodCare has performed internal cost modeling for resuming CCP collections, and validated the BARDA cost recovery rate. There are many factors driving this fee including:
  - o The majority of the units will be low titer and not qualify for CCP
  - o Antibody and titer testing costs
  - o Apheresis collections/procedure costs
  - o Donor recruitment costs given strict CCP donor qualification requirements
- Please see [AABB FAQ - Medicare Payment Policy for CCP](https://www.aabb.org/docs/default-source/default-document-library/positions/aabb-medicare-payment-policy-covid-19-faq.pdf?sfvrsn=86e4e2a9_4) for billing questions related to CCP (also found at [https://www.aabb.org/docs/default-source/default-document-library/positions/aabb-medicare-payment-policy-covid-19-faq.pdf?sfvrsn=86e4e2a9\\_4](https://www.aabb.org/docs/default-source/default-document-library/positions/aabb-medicare-payment-policy-covid-19-faq.pdf?sfvrsn=86e4e2a9_4))